Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | GHSR | Q92847 | 5/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3614996 | 0.89 | DRD2 (0.45) | DRD2ARGHSRNR1H2GPR119 | |
| SCHEMBL3294838 | 0.84 | ESR2 (0.52) | GHSRPTPN1NR1H2ESR2 | |
| SCHEMBL3602844 | 0.82 | GHSR (0.43) | GHSRPTPN1NR1H2ESR2 | |
| SCHEMBL3601158 | 0.82 | GHSR (0.43) | GHSRPTPN1NR1H2ESR2 | |
| SCHEMBL3607676 | 0.82 | GHSR (0.49) | GHSRPTPN1NR1H2ESR2 | |
| SCHEMBL3611817 | 0.81 | GHSR (0.44) | DRD2GHSR | |
| SCHEMBL25142645 | 0.81 | GHSR (0.47) | GHSR | |
| SCHEMBL17726437 | 0.81 | GHSR (0.46) | DRD2ARGHSRGPR119 | |
| SCHEMBL17391131 | 0.81 | DRD2 (0.44) | DRD2GHSRGPR119 | |
| SCHEMBL3061738 | 0.80 | GHSR (0.59) | GHSRGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | ACAT1, ACAT2, LCAT | DRD2 4578/4885AR 1232/4885GHSR 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.